Deals
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The Company and its wholly owned subsidiary, Motif BioSciences Inc., have entered into a loan Amendment and Release agreement with Hercules Capital Inc., the senior secured lender to Motif Inc, regarding certain actions which fully satisfy the conditions attached to the Company’s previously announced agreement in principle with Hercules
CYNBIOME receives funding under Investments for the Future Program (PiA), supplemented by €3M ($3.3M) of Cynbiose’s own funds
The merged companies will operate under the name Histogen and trade on the Nasdaq Capital Market under a new ticker symbol.
PDC*line Pharma announces the completion of its Series B round of financing.
The company announced it had rejected the bid, saying that it “significantly undervalues Sorrento and is not in the best interest of the Company’s stockholders.”
As AbbVie and Allergan near completion of the $63 billion merger, the two companies are shedding some assets in order to meet demands of regulators over concerns of a monopoly.
Nuvisan Pharma Services announces its acquisition of Inamed GmbH, an international CRO specialized in clinical trials with patients living with respiratory and rare diseases.
iOnctura B.V., a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, announces the closing of a EUR 15 million Series A financing.
Recipharm announces that it has this morning acquired 4,881,437 Consort Shares, representing 9.9 per cent. of the existing issued share capital of Consort Medical, at 1,010 pence per share and a further 118,563 Consort Shares, representing 0.2 per cent. of the existing issued share capital of Consort Medical at 1,000 pence per share.
Heidelberg Pharma AG announced that it has secured a financing commitment from its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany